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1. Introduction
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world.
However timely screening and treatment can dramatically impact outcomes. The association
with well-defined precancerous lesions and long asymptomatic period provides the oppor‐
tunity for effective screening and early treatment of CRC. The current options for CRC
screening are strongly anchored in evidence demonstrating utility in reducing morbidity
and mortality. This chapter will review the epidemiology of CRC, risk stratification, strat‐
egies for screening, as well as factors that threaten achieving health equity through appro‐
priate screening programs.
2. Epidemiologic trends in colorectal cancer
Worldwide CRC is the third most common cancer and fourth most common cause of death.
Interestingly this disease affects men and women almost equally (Haggar and Boushey,
2009). In the United States CRC is the third most commonly diagnosed cancer and consti‐
tutes 10% of new cancers in men and women (Society, 2011). In 2011, there were approxi‐
mately 141,120 new cases and it is estimated that 143,460 Americans will be diagnosed with
colorectal cancer in 2012 (NIH, 2009). Furthermore it is estimated up to 30% of new cases are
found in the general population without known risk factors for this disease (Imperiale et al.,
2000). Although there are still approximately one million new cases of CRC diagnosed each
year, incidence has been steadily declining over the past 15 years (Bresalier, 2009; Ferlay et
al., 2010; Kohler et al., 2011). In the United States mortality from CRC has also declined with
a 7% decrease in men and 12% decrease in women between 1980 and 1990 (Jemal et al.,
2008). Since 1990 decreases in CRC incidence and mortality have been even more substan‐
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tial, and is largely attributable to improvements in screening rates (Lieberman, 2010), espe‐
cially the growing use of colonoscopy procedures (Edwards et al., 2010). Nevertheless,
important trends remain in the worldwide epidemiology of CRC.
2.1. Geographic variations in CRC epidemiology
There is significant diversity in colorectal cancer incidence worldwide. Surprisingly indus‐
trialized nations have a remarkably greater occurrence of CRC accounting for 63% of all cas‐
es. In fact CRC incidence rates range from more than 40 per 100,000 people in the United
States, Australia, New Zealand, and Western Europe to less than 5 per 100,000 in Africa and
parts of Asia. It is notable that the US is the only country with significantly declining CRC
incidence rates for both genders, and this is most likely a reflection of better screening prac‐
tices and early prevention (Jemal et al., 2011).
While there is substantial disparity in CRC occurrence globally, CRC incidence has been in‐
creasing in places previously reporting low rates. For example the number of new CRC di‐
agnoses has been rising in a number of Asian countries that recently transitioned from low-
income to high-income economies. Individuals residing in China, Japan, India, Singapore,
and Eastern European countries were previously reported to have the lowest rates of CRC.
Countries with the highest incidence rates include Australia, New Zealand, Canada, the
United States, and parts of Europe, however incidence has started stabilizing and even de‐
clining in these regions (Haggar and Boushey, 2009; Jemal et al., 2010).
Interestingly CRC incidence seems to have a close association with location. In fact studies
show that migrants rapidly acquire the risk patterns for CRC associated with their new sur‐
roundings. For example the incidence rates in Japanese immigrants have been found to sig‐
nificantly increase after moving to the United States. Geographic influence is also evident in
a study done in Israel where male Jews of Western descent were found to have a higher like‐
lihood of developing CRC than those born in Africa or Asia. Furthermore environment may
be responsible for variations within ethnic groups. This is demonstrated by higher rates of
CRC among American Indians living in Alaska than those residing in the Southwest. Inci‐
dence rates among black males were found to range from 46.4 cases per 100,000 individuals
in Arizona to 82.4 per 100,000 in Kentucky. In white men rates range from 44.4 per 100,000
in Utah to 68.7 per 100,000 in North Dakota (The Centers for Disease Control and Prevention
[CDC], 2011).
The importance of location can also be seen by differences in CRC incidence within specific
genders. CRC mortality rates for men are lower in Western states excluding Nevada, and
higher in Southern and Midwestern states. These differences in CRC rates may be attributa‐
ble to regional variations in risk factors including diet and lifestyle as well as access to
screening and treatment. In fact one study found that up to 43% of colorectal cancers are
preventable through diet and lifestyle modifications (Perera P.S., 2012).
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2.2. Racial and ethnic variations
There is substantial evidence demonstrating racial disparities in CRC risk particularly for
black men. In the USA this group has been found to have 20% higher incidence rate and 45%
higher mortality rate from colorectal cancer compared to whites (Jemal et al., 2008; Wallace and
Suzuki, 2012). There are also significant differences in life expectancy among blacks compared
to whites. While there was a 39% reduction in mortality rate for white men between 1960-2005,
during the same period there was a dramatic 28% increase in mortality for black men (Soneji et
al., 2010). Of note incidence rates among other racial groups including Hispanics, Asian Amer‐
icans, and American Indians are lower than those among whites. The factors that underlie
these differences have not been fully elucidated but most likely encompass both modifiable
factors (e.g. smoking, socioeconomic status, body mass index, and cultural beliefs) as well as
non-modifiable factors (e.g. race/ethnicity, gender, and genetic predisposition). These findings
do suggest there is a need for appropriate risk stratification for CRC and for more aggressive
screening in high-risk populations, particularly among blacks in the United States. Such an ap‐
proach has been recommended by both the American College of Gastroenterology as well as
the American Society for Gastrointestinal Endoscopy with the suggestion to start screening
blacks at the age of 45 (Cash et al., 2010; Rex et al., 2009).
2.3. The gender gap
According to SEER 2012 statistics, the overall prevalence of colorectal cancer does not vary
substantially between the genders. The lifetime risk of being diagnosed with CRC is similar
for men 5.7% and women 5.2%. The lifetime risk of dying from CRC is also similar; 2.3% and
2.1% for men and women respectively (NIH, 2009). Even though annually the new diagno‐
ses of CRC have roughly been equal in men (187,973) and women (185,983), men have high‐
er age-adjusted CRC incidence rates (Abotchie et al., 2012). Women seem have a delay of
approximately 7-8 years in the development of advanced polyps (Jaroslaw Regula, 2012; Lie‐
berman et al., 2005). Additionally age adjusted mortality rates can be up to 35-40% higher in
men compared to women (CDC, 2011). Gender related disparities are not completely under‐
stood but may be attributable to variations in hormonal exposure (Chlebowski et al., 2004).
These biological differences related to sex raise the issue of whether men and women should
be screened differently for CRC. However current screening guidelines have not been modi‐
fied based on gender (Levin et al., 2008).
2.4. Modifiers of the epidemiologic trends
Despite some overall gains, several factors remain that impact the epidemiology of CRC.
Advancements in elucidating CRC pathogenesis allow for explanations of the above epide‐
miologic trends and have the potential for more efficient screening and treatment. It is esti‐
mated that up to 70% of CRC cases occur sporadically in individuals with no identifiable
risks (Hardy et al., 2000). Factors that predispose individuals to a higher risk for developing
CRC include any personal or family history of CRC or adenomatous polyps, inflammatory
bowel disease (IBD), and inherited genetic syndromes such as familial adenomatous polypo‐
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sis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC). Guidelines recommend ear‐
lier and more aggressive screening for this high-risk population.
As evidenced by the presence of both modifiable and non-modifiable risk factors, the patho‐
genesis of CRC seems to be influenced by a combination of genetics and the environment. In‐
deed  the  disease  results  from  the  progressive  accumulation  of  both  genetic  as  well  as
epigenetic changes in the colonic epithelium. Currently genetic tests are available that identify
patients with inherited mutations associated with FAP and HNPCC. While this technology is
promising, only 2-6% of CRC cases are attributable to common inherited mutations, suggest‐
ing other variables are playing a role in the development of this disease (Winawer et al., 2003).
Some of the environmental influences that have been investigated include the role of Strepto‐
coccus Bovis. Although infections are recognized as a major preventable cause in cancer, an in‐
fectious etiology has not been identified in cases of sporadic CRC, strongly suggesting that
more factors are involved in the development of this disease (Boleij and Tjalsma, 2012). Similar
to many other cancers, an important common thread in the pathogenesis of CRC is the pres‐
ence of chronic inflammation that is thought to increase the probability of mutagenic events
that lead to the production of oxidative species and damage DNA causing genomic instability
(Zauber et al., 2008). This is demonstrated by patients with inherited genetic mutations who
are found on colonoscopic examination to have chronic inflammatory changes that precede tu‐
mor development (Terzic et al., 2010). This can also be seen in patients colonized with S. Bovis
who are found to have inflammatory changes in the bowel wall (Terzic et al., 2010). Further
support for an inflammatory basis is found in recent studies showing aspirin and non-steroi‐
dal, anti-inflammatory drugs greatly reduce the risk of CRC (Rothwell et al., 2012).
2.5. Impact of screening on the epidemiology of CRC
Numerous studies show favorable CRC outcomes if the cancer is identified and treated at an
early stage. In fact the 5-year survival rate is greater than 90% if CRC is identified at an early
stage. However if the cancer extends beyond the colon, 5-year survival is less than 10% (Col‐
lett et al., 1999). Continuing advances in CRC therapies hold the promise of adequate treat‐
ment for advanced stages of the disease. A recent study in Nature suggests the possibility of
helping patients with advanced stage CRC with targeted drugs. This study suggests that
there are a finite number of genetic pathways in CRC that can be therapeutically targeted.
Although these findings are promising much work is still needed before there will be a cure
for CRC (Muzny et al., 2012).
Given the limited effective treatment for advanced CRC, prevention through early detection
is paramount. CRC is a model disease for routine population screening since it is prevalent,
has a long asymptomatic period, and precancerous lesions can be identified and treated
(Pezzoli et al., 2007). Compared to other cancers where the primary goal is early detection of
neoplasia, CRC can actually be prevented with detection and removal of cancer precursor
lesions (Inadomi et al., 2012). It is estimated that 30% of people over the age of 50 with no
history of CRC risk factors harbor adenomatous polyps (Alberti et al., 2012; Pezzoli et al.,
2007), and the incidence of these polyps increases with age. Early adenoma resection is asso‐
Colonoscopy and Colorectal Cancer Screening - Future Directions28
ciated with considerable reductions in CRC (Rex et al., 2009; Winawer et al., 1993b), and has
now been demonstrated to have mortality benefit (Zauber et al., 2012).
Although it is difficult to identify precisely which adenomas will undergo neoplastic trans‐
formation, there are certain pathologic features that can help predict their level of risk: in‐
creased size ≥10 mm, increased number of 3 or more adenomas, villous histology, and high-
grade dysplasia (Alberti et al., 2012; Lieberman et al., 2012). Most adenomas undergo a
similar progression to invasive cancer termed the adenoma-carcinoma sequence (Levin et
al., 2008; Sano et al., 2009). Given that these cancer precursors are often asymptomatic, there
is compelling evidence to support early screening for healthy individuals. In fact the aver‐
age-risk individuals compose 70-75% of the CRC population (Lieberman, 2010). In response
to mounting evidence suggesting that screening of average-risk individuals allows for early
cancer detection and prevention, CRC guidelines from several organizations were updated
in 2008 (USPSTF, 2008).
2.6. CRC prevention tests
Colonoscopy allows for the direct visualization of the entire colon and for the potential to
remove lesions that are identified. Results from the National Polyp Study confirm that colo‐
noscopy and adenoma removal is associated with decreased rates of developing colon can‐
cer in the future (Winawer S.J., 2006) and reduces mortality (Zauber et al., 2012). The finding
that mortality is reduced by polypectomy is of major significance because it suggests that
colonoscopy can identify a subset of adenomas which can potentially become aggressive
cancers and provides further evidence that colonoscopy is in fact the best screening option
because of its added benefit of decreased mortality, particularly in individuals at increased
risk. In patients with no lesions detected during a screening colonoscopic examination, the
interval for follow-up surveillance can be extended to 10 years compared to 5 years for sig‐
moidoscopy (which visualizes only the left side of the colon) along with FOBT every 3 years.
The known draw backs to colonoscopy include the need for bowel prep, sedation that may
be associated with cardiopulmonary risks, higher cost compared to other methods, associa‐
tion with greater risk of bleeding and perforation, and a miss rate of up to 5% for malignant
colon lesions.
While colonoscopy remains the gold standard for CRC prevention, economic constraints
and patient attitudes may prevent screening with this technique. In an effort to improve
participation alternative tests have been endorsed. There are a range of screening meth‐
ods that are categorized into two major groups, prevention and detection. Prevention tests
detect cancer as well as pre-cancerous polyps, and are generally structural exams such as
the  colonoscopy,  flexible  sigmoidoscopy,  CT  colonography,  and  double-contrast  barium
enema. Detection tests are only able to identify CRC lesions and consist of fecal tests in‐
cluding the fecal immunochemical test (FIT), fecal occult blood testing (FOBT), and Fecal
DNA testing (Rex et al., 2009).
Flexible Sigmoidoscopy remains an acceptable alternative to colonoscopy for colorectal can‐
cer screening (Levin et al., 2008; USPSTF, 2008; Winawer et al., 2003; Winawer et al., 1997).
Although both screening techniques are similar, sigmoidoscopy requires more frequent
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screenings at 5–year intervals and the benefits are confined to the distal colon only. In addi‐
tion the USPSTF recommends screening with FOBT every 3 years (USPSTF, 2008). Prior
studies have demonstrated a significant mortality benefit for the section of the colon exam‐
ined (Wilkins and Reynolds, 2008). A recent study in the NEJM confirmed this data showing
that flexible sigmoidoscopy decreases CRC incidence and mortality (Schoen et al., 2012). The
advantages of sigmoidoscopy include lower cost, lower risk profile, and need for less bowel
preparation compared to colonoscopy. However a major setback for this alternative is that
polyp visualization is limited to the distal colon. Studies have shown that up to 30% of pa‐
tients with distal colon cancer also have synchronous proximal lesions that will be missed
by sigmoidoscopy (Francois et al., 2006; Imperiale et al., 2000; Lieberman et al., 2000). As
such individuals with polyps in the distal colon should undergo follow up with colonosco‐
py given the increased prevalence of synchronous right-sided lesions. Screening only 50% of
colon will preclude detection of the lesions in the portion of the colon not within reach of the
sigmoidoscope. This test would also not be an appropriate screening tool for women, pa‐
tients over the age of 60, patients with HIV, and African Americans who have a higher like‐
lihood of harboring proximal polyps (Bini et al., 2006; Lieberman et al., 2000; Lieberman et
al., 2005; Schoenfeld et al., 2005).
Double contrast Barium enema allows for visualization of the entire colon and must be com‐
pleted every 5 years. Its high polyp miss rate (as high as 23%), lack of therapeutic interven‐
tion (another procedure is needed to remove detected polyps), and concerns regarding
radiation exposure, have limited its use (Toma et al., 2008; Wilkins and Reynolds, 2008).
CT colonography is able to provide information about the entire colon and has been pro‐
posed as a possible screening option for patients who decline conventional colonoscopy.
This test is less invasive compared to conventional colonoscopy, is associated with de‐
creased risk of perforation and does not require sedation (Lieberman, 2010). Not only are de‐
tection rates far superior to the barium enema, but CT colonography (CTC) has comparable
sensitivity to colonoscopy for polyps 10mm or greater in size (Johnson et al., 2008). However
relative to other options, this modality is costly, and has poor sensitivity for polyps less than
7mm (Lieberman, 2010). Due to insufficient evidence for performance metrics this test is cur‐
rently not supported by established guidelines. The United States Preventive Services Task
Force expresses additional concern about the impact and extra costs related to following-up
extra-colonic findings (USPSTF, 2008). In fact an estimated 27% to 69% of tests performed
uncover abnormal extra-colonic findings (Lieberman, 2010). More studies are needed to as‐
sess this procedure’s benefits and risks, particularly to determine whether this method may
be missing significant lesions.
Capsule Endoscopy provides direct visualization of the colonic mucosa via an ingestible
capsule with video cameras at both ends that wireless transmits images to a receiver. Given
that bowel motility significantly affects results, this test is not performed regularly and is not
supported by current guidelines.
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2.7. CRC detection tests
Fecal occult blood testing (FOBT) is an annual stool test that detects cancer at an early stage.
The USPSTF now specifically recommends the high-sensitivity guaiac-based testing (He‐
moccult Sensa) over the standard guaiac-based testing (Hemoccult II) (USPSTF, 2008). Based
on the premise that colon cancer intermittently bleeds, the FOBT tests for blood by detecting
the peroxidase activity of heme (Lieberman, 2010). Not only is the test economical and con‐
venient, patients with a positive test result have an almost 4 fold increased likelihood having
cancer (Winawer et al., 2003). In fact studies have found FOBT reduces mortality by approxi‐
mately 33% over a 10-year period (Lieberman, 2010). Another study reported approximately
20% reduction in mortality when FOBT was compared to controls over an 18-year period
(Lieberman, 2010). Supporters of the FOBT question whether invasive measures such as the
colonoscopy are harmful given that computer simulated modeling shows similar life-years
gained in both tests (Zauber et al., 2008). Furthermore advocates assert that FOBT has the
greatest potential for impact at the population level because it is directed at healthy people
(Harvard Medical School, 2012). Additionally asymptomatic people may be more willing to
participate in a less invasive and generally less inconvenient test.
While a case can be made that FOBT has some quantifiable mortality benefits, evidence sug‐
gests that colonoscopy is still the superior screening option. FOBT has many disadvantages.
One major drawback of this modality is the high false positive rate because the test is not
specific for human blood. In fact the test will not be accurate if patients consume red meat or
any other peroxidase containing substances. Additionally three-stool sample are required on
separate days (Lieberman, 2010). Single sample FOBT is estimated to miss 95% of CRC (Wil‐
kins and Reynolds, 2008). Furthermore the test must be repeated annually to be effective. In
addition to these drawbacks, this test only detects potentially high-risk individuals which
means that abnormal test results require subsequent follow up with colonoscopy. Compli‐
ance with all of the aforementioned recommendations is unknown making the effectiveness
of the test uncertain. In fact one survey found that up to 30% of doctors recommended inap‐
propriate forms of follow up rendering the FOBT not useful (Nadel et al., 2005). Despite
these drawbacks the FOBT sampling test is still preferable to the no screening option.
Fecal immunochemical testing (FIT) is a newer test that is easier to use and specific for hu‐
mans. This means that the FIT is less susceptible to interference by diet or drugs. This mo‐
dality uses antibodies to detect human blood components such as hemoglobin and albumin
in stool samples (School, 2012). This alternative is appealing because it is less invasive than
colonoscopy but potentially more accurate than the FOBT. Studies show over 50% sensitivi‐
ty for cancer after using as small an amount as one stool sample (Lieberman, 2010). FIT may
be superior to the FOBT given that one study showed higher participation in the FIT group.
Participation is key for fecal tests making the previously mentioned study clinically rele‐
vant. However no randomized trials have shown that FIT decreases mortality (Wilkins and
Reynolds, 2008).
Given that participation may be negatively impacted by hesitation to undergo colonoscopy
screening, a recent study investigated whether FIT can serve as a valid screening alternative
and no significant differences were found between FIT and colonoscopy in terms of partici‐
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pation (Quintero et al., 2012). Furthermore colonoscopy still detected substantially higher
numbers of cancerous polyps. It is difficult from this study to declare that FIT testing is non-
inferior because of colonoscopy’s mortality benefit.
Fecal DNA testing detects a finite number of gene mutations in stool samples associated
with colon neoplasia (Alberti et al., 2012). One large prospective trial found stool DNA test‐
ing to have greater sensitivity for cancer than standard FOBT (Imperiale et al., 2004). Fur‐
thermore patients were found to prefer fecal DNA testing to both FOBT and colonoscopy
(Wilkins and Reynolds, 2008). However this option is not recommended by current guide‐
lines because of insufficient evidence. Also there have been other studies comparing stool
DNA testing to FOBT that suggest this fecal DNA testing does not measure up in terms of
cost or efficacy (Lansdorp-Vogelaar et al., 2010).
2.8. Which screening test should be done?
Each of the aforementioned screening options has strengths and setbacks, however patient
adherence to CRC screening remains more critical than the specific method chosen (Vijan et
al., 2001). Simply put, the best test is the one that the patient accepts and complies with. De‐
spite mounting evidence that screening is life saving, screening rates remain surprisingly
low for this preventable cancer. In fact awareness of the importance of CRC screening has
only recently started to approach that of other cancers. Statistics indicate only 24% of Ameri‐
cans have completed the FOBT within the past few years and only 57.1% have ever had a
sigmoidoscopy or colonoscopy (Wilkins and Reynolds, 2008). Data from the NHIS, a nation‐
al survey of the general population, shows that only 58.3% of the US population met recom‐
mendations for CRC screening in 2010 (Shapiro et al., 2012). This is increased from 54.5% in
2008. Although there has been progress in the use of CRC testing, 40-50% of individuals
over the age of 50 still are not receiving routine screening for colorectal cancer.
It is apparent from these suboptimal screening rates that there is a demand for novel screen‐
ing strategies that are not only effective but also economical and non-invasive. Continued
research in this field is ongoing and in a fascinating study published in Gut, Citarda et al
(Citarda et al., 2001) took steps towards attempting to find this desired formula. Their study
is evidence of the increasing knowledge about the molecular properties of cancer. Based on
the theory that a specific cancer smell exists, they found that a trained labrador retriever
could detect the presence of colorectal cancer with 91% sensitivity and 99% specificity in
breath samples and 97% sensitivity and 99% specificity in watery stool samples. Surprising‐
ly the study dog’s ability to detect cancer was not confounded by benign colorectal disease,
inflammatory bowel disease, or smoking. Even though the routine use of canines for cancer
screening is not practical, this study suggests there is potential for future screening tests
based on cancer-specific chemical compounds.
2.9. Cost effectiveness of CRC screening
CRC screening has been found to reduce mortality and to be cost-effective. The challenge
remains to make screening affordable and available to individuals who will experience the
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greatest benefit. Several models have been proposed to estimate the costs of various screen‐
ing programs. The 2005 Institute of Medicine comprehensive summary of CRC screening ef‐
fectiveness concluded that all of the screening options are relatively comparable in terms of
life-years gained as well as cost when compared with a no-screening option. FOBT was the
least costly option, however most modalities are estimated to cost <$40,000 per life-year
saved (Lieberman, 2010; Pignone et al., 2002). However it is difficult to rely on these models
alone as they may not be entirely accurate and are not able to account for other factors such
as patient compliance. In general cost benefit analysis studies suggest that CRC screening is
overall a cost-effective measure and it is estimated that routine screening can save more
than 18,800 lives per year (Maciosek et al., 2006; Wilkins and Reynolds, 2008).
2.10. Surveillance guidelines
Currently the United States Multi-Society Task Force (MSTF) on CRC supports a 10-year inter‐
val between subsequent screening colonoscopies for average risk patients. Case-control and
observational studies indicate that the mortality benefit from colonoscopy lasts at least 10
years. However patients who are found to have adenomas on baseline colonoscopy are at in‐
creased risk of developing future adenomas and cancerous lesions (Martinez et al., 2009). Cer‐
tain higher-risk patients can develop cancer as soon as 3-5 years after a colonoscopy. These are
termed interval cancers. These patients require a shorter interval between subsequent follow
up because this has been shown to reduce colorectal cancer incidence by as much as 66% (Cit‐
arda et al., 2001; Winawer et al., 1993a). Guidelines from the GI consortium panel advocate re‐
peat colonoscopy 5 years after removal of a low-risk polyp and after 3 years if the polyp has
higher risk features. The selection of a 3-year screening interval for subsequent follow-up is
based on evidence that shows detection of advanced lesions is not improved at 1 year versus 3
years (Winawer et al., 1993b). Further research is still needed to determine whether a single
negative follow up colonoscopy is sufficient (Lieberman et al., 2012).
The use of risk stratification to determine the optimal screening interval is important be‐
cause physicians that refer patients for surveillance at intervals shorter than recommended
may be exposing patients to unnecessary risks and costs (Lieberman, 2010). In fact a recent
study revealed underuse of colonoscopies in high-risk patients and overuse in low risk pa‐
tients. By ineffective allocation of resources high-risk patients are placed at increased risk for
developing cancer. Furthermore optimization of screening is important in light of low
screening rates for a preventable cancer. Customized screening recommendations based on
risk allows for more streamlined and effective screening leaving resources that can be devot‐
ed to colon cancer education targeting the challenging subset of the population at high risk
with poor adherence. Ultimately screening program success depends not only on quality
but patient participation (Lieberman et al., 2012). In addition to risk stratification, the MSTF
on CRC believes that high-quality baseline examination is key for effective surveillance. In‐
terval cancers have been found to occur more frequently in patients with negative baseline
exams. There is evidence to suggest that important lesions are often missed at baseline colo‐
noscopy and it is estimated that up to 17% of 10 mm lesions are missed. This variability in
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adenoma detection rates may be attributable to biologic differences in missed adenomas or
disparities in endoscopist proficiency.
3. When to start screening?
As with any effective screening technique, the most important issue is always when to start
offering the test. Although the lifetime risk of CRC is estimated to be 6%, we now under‐
stand that the chance of developing the disease increases with age. In the United States the
annual incidence of CRC in people of ages 50 to 54 was found to be approximately double
that found in individuals ages 45 to 49 (Imperiale et al., 2000). A successful screening test, if
used on 100% of the population has the potential to save many more lives than if the test is
used on only a portion of the population. However given limited medical resources, strate‐
gic optimization is necessary for maximum impact. Current recommendations support ini‐
tiation of screening at age 50 for average risk men and women with earlier screening
recommended for high-risk populations (Levin et al., 2008; Rex et al., 2009; USPSTF, 2008;
Winawer et al., 2003). In addition to identifying optimal timing for initiation, the goals of
screening have shifted to focus on cancer prevention rather than simply cancer detection
(Winawer et al., 2003). As a result recent guidelines from the American College of Gastroen‐
terology (ACG) and USPSTF now endorse colonoscopy as the preferred modality for screen‐
ing (Rex et al., 2009; USPSTF, 2008).
Screening guidelines must be tailored to maximize benefit while minimizing cost to both the
individual and society as a whole (Rembold, 1998). The term “number needed to screen” is
defined as the amount of people needed to be screened over a timed duration to prevent one
death or adverse event. Many studies have looked at the cost-effectiveness of colon cancer
screening with the three most common methods (i.e. fecal occult blood annually, sigmoido‐
scopy every 5 years, colonoscopy every 10 years - all beginning at age 50 and stopping at
age 85). Current estimates range from $6,000 – $11,900 spent for every year of life gained
(Maciosek et al., 2006; Telford et al., 2010). In contrast, studies on the cost effectiveness of
screening mammography estimate roughly $58,000 spent for every one year of life gained
(Stout et al.). Many experts suggest that a screening policy should result in expenditure of
$50,000 or less per year of life gained. Thus, it is clear that colon cancer screening makes
sense medically and financially. The question of when colon cancer screening should begin
and end remains, and is a complex one. While colon cancer is typically a disease of the mid‐
dle age to elderly, there are many groups of high-risk patients that need screening much ear‐
lier than current guidelines. The remainder of this section will attempt to elucidate screening
strategies in low-risk, average-risk, and high-risk groups.
It is important to emphasize that colon cancer is a diverse entity with many paths leading to
a common endpoint, carcinoma. The adenoma-carcinoma sequence can encompass a multi‐
tude of genetic mutations that lead to the eventual progression to cancer (i.e. mismatch re‐
pair genes, tumor suppressor genes, base excision repair genes, micro-satellite genes). No
single mutation results in adenocarcinoma, but as mutations compile, a carcinoma eventual‐
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ly develops. For the majority of colon cancers, there is a significant amount of time between
development of an adenoma and its progression to a malignant lesion. The time interval for
progression is often determined by type of adenoma found. Current studies estimate that
the dwelling time for a tubular adenoma is roughly 26 years, 9 years for tubulovillous ade‐
noma, and 4 years for a villous adenoma (with an overall annual transition rate of 2.2%)
(Chen et al.). It is this significant window period of detection time that allows screening for
colon cancer to be so incredibly effective, and thus important to optimize timing and fre‐
quency of screening. While these concepts hold true for the majority of colon cancers, not all
cancers are created equal. Certain high-risk groups progress to cancer much more rapidly
than the above data suggests, and these groups will be detailed ahead.
3.1. Distribution of colorectal cancer types
The vast majority (70-75%) of colorectal cancers develop in sporadic (nonhereditary) fashion
and no risk factors are identified in the individuals. The next most common form (15-20%)
occurs in those with a family history of colon cancer (excluding known cancer syndromes).
Hereditary Non-polyposis colorectal cancer (i.e. Lynch Syndrome) makes up roughly 3-8%.
Familial Adenomatous Polyposis 1%, and Colitis Associated Cancer (i.e. Inflammatory Bow‐
el Disease) also 1% (Winawer et al.). Keeping these figures in mind, colon cancer screening
has the largest absolute impact on average-risk individuals. As such, the next section will
focus on screening recommendations for the average-risk group.
3.2. Approach to average-risk individuals
As mentioned before, colon cancer is a disease of the middle age to elderly. According to a
review by the National Cancer Institute conducted from 2005-2009, the median age at time
of diagnosis of a colorectal cancer is 69. Thus, if we extrapolate from the data provided pre‐
viously (~2% annual transformation from adenoma to carcinoma), we can see that it makes
sense to exclude the younger population from screening tests. In fact, the most recent
USPSTF recommendations support the initiation of colon cancer screening in average-risk
individuals at age 50 (Grade A Recommendation) (USPSTF). These recommendations were
made based in part on the results of two microsimulation models (MISCAN and SimCRC
models) that incorporated current data on colon cancer incidence and adenoma progression,
and simulated the natural history of colon cancer in a large population. The models then es‐
timated the life-years gained if screening colonoscopy was performed vs. no screening at all.
Further data analysis detailed age to begin screening, age to stop screening, and time inter‐
vals between screening. The models concluded that the optimal age to initiate screening is
50 (when compared to ages 40 and 60). Of note, one simulation showed better outcomes
when screening was initiated at age 40, however the alternate simulation did not corrobo‐
rate the data. The Task Force concluded, “Because the evidence for both adenoma preva‐
lence at age 40 and the duration of the adenoma-carcinoma sequence is weak, we restricted
further analysis to start ages of 50 and 60.” This led to the recommendation of initiating
screening at age 50. Regarding interval time period between colonoscopy, the authors re‐
viewed data on 5-year, 10-year, and 20-year intervals. They concluded, as could be expected,
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shorter intervals resulted in more life-years gained (their primary endpoint). However,
when comparing 5-year to 10-year, there was only a modest increase in life years gained
when compared to the corresponding increase in colonoscopies performed. 20-year intervals
resulted in significantly less life-years gained, so was not considered optimal. While these
authors agree with the recommendations by the USPSTF for average-risk individuals, it is
important that practitioners further tailor their screening strategies based on several addi‐
tional factors. As mentioned, 75% of colon cancers occur in average-risk individuals, thus
representing a large absolute number of persons. As such, there is much variability and as‐
sociated risks among the average-risk population.
Factors that increase the risk for colorectal cancer or are protective have been identified.
While these factors have not been incorporated into the USPSTF Guidelines, knowledge
about their existence and influence on overall risk may be helpful in directing clinicians to‐
ward screening colonoscopy practices. Additionally, and some may argue more important‐
ly, clinicians must take into account a patient's expected adherence to their colonoscopy
recommendations. Will the patient have regular and predictable access to a skilled gastroen‐
terologist? Will they be willing to comply with frequent colonoscopy should their risk fac‐
tors or findings require it? A new concept known as once in a lifetime screening with
colonoscopy is being proposed as an effective technique in some groups. Knowledge of risk
factors can be especially helpful in these cases, in which a clinician can strongly encourage
adherence to recommendations based on each individual's risk factors. Additionally, it is
important to note that the following discussion applies only to individuals classified as aver‐
age-risk, and excludes those with a family history, diagnosed genetic condition, and Inflam‐
matory Bowel Disease. These groups will be discussed separately.
3.3. Modifiable CRC risk factors
To date, several modifiable risk factors have been clearly linked with the development of
colorectal carcinoma. Starting from the 10,000-foot view, many of the risk factors can be col‐
lectively grouped under the heading of total energy balance (i.e. caloric intake vs. caloric ex‐
penditure). Numerous studies have shown a clear link between Body Mass Index and
resultant risk of colon cancer. For example, investigators looked at the lifetime incidence of
colon cancer among the Framingham Cohort in Massachusetts, and divided the group by
age group to a 30-54 year old group and a 55-79 year old group. They then looked at the
overall incidence of colon cancer among the groups, and related the information to average
Body Mass Index. In the 55-79 year old group, they separated the cohort into BMI >30 and
BMI <30 groups. They noticed a significant 2.4 fold increased risk for the development of co‐
lon cancer for those with a BMI >30 (95% CI: 1.5-3.9) (Moore et al., 2004). Interestingly, the
same study also analyzed the results with relation to waist size measurement. As BMI can
be notoriously misleading, especially among males, the authors pursued this alternate meas‐
ure for further support. They concluded that central adiposity (defined as a waist size >39
inches), was associated with a two-fold increase in risk for colon cancer. They further noted
that the risk increased linearly with increases in waist size. This data has been replicated
among many other studies, in both men and women. A large study by the Nurses' Health
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Study Research Group concluded similarly that increasing BMI is associated with increased
risk of colon cancer, and particularly noted a higher risk among women with an increased
waist-to-hip ratio (Martinez et al., 1997). It is now widely accepted that obesity, and particu‐
larly central obesity, is an independent risk factor for the development of colon cancer. Sev‐
eral theories have been proposed as to why exactly this clear association exists. For now, the
most supported theory proposes that insulin resistance (along with hyperinsulinemia and
increased Insulin-like Growth Factor-1) plays a large role in this relationship. In fact, a re‐
cent meta-analysis has concluded that Diabetes Mellitus is itself an independent risk factor
for colon cancer. Even after controlling for physical activity, smoking, and obesity, the au‐
thors found an increase in relative risk among those with Diabetes Mellitus of 1.43 and 1.35
in men and women, respectively (both statistically significant) (Yuhara et al., 2011). Patho‐
physiologically, both insulin and IGF-1 are involved in cell proliferation and regulation of
apoptosis and it is enough to recognize that states with elevated levels of both hormones
have been clearly linked to increased risk for colon cancer. Additionally, multiple studies
have looked at the effect of physical activity and its influence on colon cancer. These studies
and their respective meta-analyses have shown clearly an inverse relationship between
physical activity and colon cancer. Among data taken from the group exhibiting the highest
level of exercise, one study showed a 50% reduction in lifetime colon cancer risk (Colditz et
al., 1997). Thus, an important conclusion can be reached based on the data reviewed as well
as others: obese, sedentary individuals are at higher risk for colon cancer. While the USPSTF
guidelines do not currently reflect this information for screening recommendations, clini‐
cians most certainly can make use of it to provide patient-centered care. Patients should be
counseled regarding overall health and the potential for primary prevention of colon cancer
via improved dieting and exercise habits.
The next most common modifiable risk factors a clinician is likely to encounter is tobacco
and/or alcohol use, both clearly linked with colon cancer. Multitudes of studies have been
undertaken in the last two decades examining the potential link between cigarette smoking
and colorectal cancer. A meta-analysis from 2009 conducted by Liang et al examined 36 such
studies (Liang et al., 2009). The results of the analysis showed a clear association between
age of initiation of tobacco use, amount smoked per day, and total duration of tobacco use.
Data showed a relative-risk of 1.38 for an increase in 40-cigarretes per day, 1.20 for an in‐
crease of 40 years total duration, and 1.51 for an increase of 60-pack years. Interestingly, they
also noted a predilection for rectal cancer over colon cancer when analyzing incidence of
site-specific carcinoma. Next, studies emerging over the last decade have begun to note in‐
creases in risk for colorectal cancer even in light to moderate alcohol use. A pooled analysis
of 8 cohort studies involving nearly 490,000 men and women was published in the Annals of
Internal Medicine in 2004. Data showed, when compared with non-drinkers, a relative-risk
of 1.41 (CI 1.16-1.72) in individuals who consumed 45g of daily alcohol (roughly three
drinks) (Cho et al., 2004). There was no statistically significant correlation among daily con‐
sumption of 30-44g/daily. More recently, a meta-analysis from 2011 from the Annals of On‐
cology examined 27 cohort studies and 34 case-control studies (Fedirko et al., 2011). They
also concluded a strong association between alcohol consumption and colorectal cancer risk.
The association was strongest among heavy drinkers, relative-risk 1.82 if >100g/day. Surpris‐
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ingly, they even found a statistically significant increase in relative-risk to 1.07 for individu‐
als drinking one alcoholic beverage per day (10g/day), which throws into question the
current recommendations of the USDA (two drinks or less daily for men, one drink or less
daily for women). Interestingly, even stronger associations were noted in studies examined
the Asian population (specifically Japanese men). Clearly, there is a link between both tobac‐
co and alcohol use and risk of colorectal cancer. Over the next few years, additional studies
and meta-analyses will likely emerge further elucidating just which populations are at risk
and what usage levels are most harmful. For now, clinicians should clearly state that tobacco
use and even light daily alcohol ingestion increases their likelihood of developing colorectal
cancer. As the current data suggests only a modest increase in relative-risk, this information
may be more pertinent among individuals with additional risk factors. Clinicians should
certainly take a patient's tobacco and alcohol use into account when determining how fre‐
quent they will advise screening colonoscopies.
3.4. Protective measures against CRC
Just as risk factors have been identified, there are also several clear factors that are protective
against colon cancer. Physical activity was discussed earlier, thus will not be repeated here,
but suffice it to mention again that it is highly protective against colon cancer. Moreover, the
medical community already advocates daily exercise for a multitude of other health bene‐
fits, and the fact that it also protects against colon cancer would not alter a clinician's man‐
agement of colonoscopy screening. However, several studies have clearly shown a
protective relationship between common pharmaceuticals and colon cancer. Both Aspirin
and Non-steroidal anti-inflammatory drugs have been shown to decrease the incidence of
colon cancer. Studies from as early as the 1980s began to show a relationship between anti-
inflammatory medications and colon cancer. Initial studies performed on patients with
Rheumatoid Arthritis, as they were often on chronic NSAID therapy, were the first to show
this relationship in the 1980s. Further studies conducted in patients on long-term aspirin
therapy showed similar results. The exact mechanism by which anti-inflammatory medica‐
tions provide this protective benefit currently remains unknown. Several hypotheses exist
which primarily center on COX-1 and COX-2 inhibition, as they are known to promote in‐
flammation, tumorigenesis, and angiogenesis. In a study published in the Lancet in 2007 by
Flossman et al, British researchers pooled data from two large Aspirin trials in the UK (Brit‐
ish Doctors Aspirin Trial, UK-TIA Aspirin Trial) (Flossmann and Rothwell, 2007). Among
patients with complete compliance for 5 years or more of aspirin therapy, they found a stat‐
istically significant relative-risk of 0.26 (CI 0.12-0.56). The effect was less substantial among
non-compliant patients, but nevertheless protective (RR 0.37). It is important to note in this
study, as in many other studies, the protective benefit was most clearly seen after a latency
period of at least 10 years. Moreover, study data pooled from trials related to cardiovascular
protection often have used differing doses of aspirin (or NSAIDs). At this time, no clear
dose, duration of therapy or type of NSAID has shown to be of greatest benefit in primary
colorectal cancer chemoprevention. As such, the USPSTF has not recommended NSAIDS as
a primary preventive measure for colorectal cancer. As more and more studies specifically
geared and powered toward colorectal carcinoma prevention (as opposed to data analysis of
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trials geared toward cardiovascular effects), it can likely be expected that clearer relation‐
ships between NSAID type, dosing, and duration will be elucidated. As it is not officially
recommended by the USPSTF, clinicians are not currently advocating for NSAID use as pri‐
mary prevention. However, a large portion of those at greatest risk for developing colorectal
cancer (i.e. middle-age to elderly) are already on Aspirin for its cardiovascular benefits.
Thus, clinicians can take this fact into account when assessing an individual's colorectal can‐
cer risk. Again, there is no current recommendation to decrease screening intervals in pa‐
tients on Aspirin therapy, however, when taken collectively with other risk factors,
clinicians may further tailor how aggressive they wish to be with screening.
Another common protective measure a clinician may encounter regards the use of post-
menopausal hormonal therapy. Again, as early as the 1980s, studies emerged showing an
unexpected link between hormonal therapy and colorectal cancers. As in many other associ‐
ations, the exact mechanism by which estrogen/progestin can inhibit cancer development is
unknown. However, speculations on its pathophysiology are under active investigation. Re‐
searchers hypothesize that hormonal therapy can alter levels of bile acids, Insulin-Like
Growth Factor-1, and IGF Binding Protein-3. Moreover, estrogen receptors have been found
on colonic epithelial cells, and it is unclear if this may also provide a route of protection.
Nevertheless, numerous studies (one of which will be described below) have shown the in‐
verse relationship between hormonal therapy and colon cancer risk. In a prospective study
of nearly 57,000 women (taken from the Breast Cancer Detection Demonstration Project)
published in 2009, Johnson et al looked at hormonal therapy (including estrogen alone, com‐
bination with progestin, and duration of therapy) and its relation to colon cancer incidence
(Johnson et al., 2009). Results are astoundingly clear that hormonal therapy is protective
against colon cancer. The results were as follows: ever users of unopposed estrogen RR 0.83
(95% CI, 0.70-0.99), current users unopposed estrogen >10 years RR 0.74 (95% CI, 0.56-0.96).
The results among estrogen + progestin users showed an even stronger relationship: estro‐
gen + progestin RR 0.78 (95% CI, 0.6-1.02), estrogen + sequential progestin RR 0.64 (95% CI,
0.43-0.95), and strongest effect with 2-5yr use of estrogen + sequential progestin RR 0.52
(95% CI, 0.32-0.87). Similar studies conducted by the WHI (Women's Health Initiative) have
shown similar results for estrogen + progestin therapy, but not estrogen therapy alone. Inter‐
estingly, they also noted that although the frequency of cancer was less in the hormonal
group, the cancers were detected at later stages (increased lymph node involvement and
metastatic disease) (Chlebowski et al., 2004). So, as before, we have clear evidence of a pro‐
tective measure against colon cancer. Unfortunately, the same WHI trial showed an increase
in myocardial infarction, stroke, dementia, pulmonary emboli, and breast cancer among hor‐
monal therapy users. As such, there have been no widespread recommendations for pri‐
mary prevention of colorectal cancer by means of hormonal therapy. However, clinicians
may encounter women who are on hormonal therapy. While estrogen therapy alone may
not have clear benefits, estrogen + progestin therapy has repeatedly shown to be of benefit
in prevention of colorectal cancer. In fact, based on the results of the first-mentioned study,
risk was decreased by a staggering 25-46%. Taking this information into account, assuming
no additional risk factors exist, and clinician may be able to tailor their screening colonosco‐
py frequency toward a less aggressive and frequent approach.
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A clinician may also encounter questions from a patient regarding diet recommendations.
While a healthy, balanced diet high in non-processed, low animal fat calories is always recom‐
mended, there has been non conclusive data regarding diet and its relation to colorectal cancer.
As such, the decision on when to initiate and how often to perform screening colonoscopies
should not be influenced by a patient's diet. It is possible that more clear relationships will be
clarified in the future, but for now, data displaying strong associations does not exist.
The next question that must be answered is what role should gender and race/ethnicity of a
patient play in a clinician's screening colonoscopy recommendations? According to the most
recent data from the Center for Disease Control (CDC) males have a higher incidence of col‐
orectal cancer vs females (52.7 vs. 39.7/100,000) (Prevention). The highest incidence is found
in African American males (62/100,000), followed by Caucasian males (51.5/100,000). His‐
panics, Asians, and Native American/Alaskan Native groups all had a lower incidence than
the comparative African-American and Caucasian groups in both the male and female cate‐
gories. When comparing death rates from colorectal cancer by race, again males have an
overall higher rate vs. females (20.2 vs 14.1/100,000).(NIH, 2009) African-American males
displayed the highest rate at 29.8/100,000, and African-American Females the next highest
rate at 19.8/100,000. The remainder of the groups showed death rates below the average of
respective male and female groups analyzed. Compiling the above data, it is evident that
African-Americans are most affected by colorectal cancer in comparison to other race/ethnic‐
ities. In fact, a study examining 5-year survival rates among Caucasians vs. African-Ameri‐
cans (among all stages of colorectal cancer) revealed a staggering difference of 64% vs. 52%
(Ries). Initially, arguments were made postulating that perhaps the African-American com‐
munity rate of screening colonoscopy was much lower, thus accounting for the higher inci‐
dence and mortality rate. According to the CDC data on screening rates, Caucasians are
most screened at 66.2% and African-Americans are next most screened at 62.9% (Rim S.H.,
2011). The lowest screening rate is found in the Hispanic population at 51.2%. While Afri‐
can-Americans have a higher mortality rate from colorectal cancer, it is clear that it is not
solely due to inadequate screening, as African-Americans have much higher screening rates
than Hispanics, yet also a much higher mortality rate. A study examining this finding con‐
cluded that African-Americans are more likely to be diagnosed at an earlier age and present
at later stages of disease, as compared to Caucasians, however this data has not been consis‐
tently replicated (Chien et al., 2005). Another study postulated that socioeconomic status
and access to medical care may be partially involved in this mortality discrepancy (Wudel et
al., 2002). This study found that African-Americans are more likely to be treated at city hos‐
pital vs university hospitals (which are associated with better outcomes). However, when
comparing survival data even among Caucasians and African-Americans at each type of
hospital, African-Americans fared worse. Another study has pointed to type of care offered
(i.e. adjuvant chemotherapy and radiation) as a potential factor (Govindarajan et al., 2003).
This study found that African-Americans are treated less with both chemotherapy and radi‐
ation therapy vs. Caucasian patients. It is still unclear why exactly African-Americans are
more often diagnosed and more often killed by colorectal cancer. Regardless of the reason, it
is clear that there is a difference that needs to be addressed. It seems that while the reasons
are being elucidated, more aggressive screening among African-Americans needs to be es‐
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tablished. Data may eventually and conclusively show that colorectal cancer appears earlier
and is more aggressive in African-Americans. In the meantime, these authors would argue
for earlier age at initiation of screening and more frequent screening intervals.
Finally, in the average-risk population, the issue of access to colonoscopy need always re‐
main in the back of a clinician's mind. Many patients may not have access due to socioeco‐
nomic or geographic barriers, or simply they may choose not to undergo screening based on
underlying psychological barriers or misconceptions regarding colon cancer and/or colono‐
scopy. As mentioned previously, many organizations are working toward colon cancer and
screening awareness, however clinicians must keep public unawareness as part of their
screening practice. If a patient presents at age 45 and there is concern for eventual adherence
to the screening guidelines at age 50, he/she should be screened at age 45.
3.5. Risk associated with family history of CRC
As mentioned previously, the next largest group of the population diagnosed with colon
cancer involves those with a family history (excluding individuals with a known colorectal
cancer syndrome). This group makes up ~15-20% of all diagnoses. Currently, there are mul‐
tiple efforts and studies looking into what exactly confers this higher risk among individuals
with a positive family history of colon cancer. At this time, it remains unclear what genetic
and/or environmental factors are involved in the pathogenesis, however, it is abundantly
clear that patients with 1st degree relatives diagnosed with colon cancer, are at a significantly
higher risk of developing colon cancer themselves. In fact, in one of the seminal studies pub‐
lished on the topic from the New England Journal Of Medicine, individuals with one 1st-de‐
gree relative with colon cancer were found to have a 1.7 fold increase in their own risk for
colon cancer (Rex et al., 2009). This risk increased further as the number of diseased 1st-de‐
gree relatives increased as well. Further, they found that the increased risk was irrespective
of location of diagnosed tumor in the relative (i.e. proximal vs. distal site of malignancy). As
such, the American College of Gastroenterology revised its guidelines regarding individuals
with a positive family history. If an individual has a 1st degree relative that was diagnosed
with colon cancer before the age of 60 (or 2 or more relatives with colon cancer or advanced
adenomas irrespective of age at diagnosis), they are considered to have a positive family his‐
tory. If a patient is identified as having a positive family history, they should then begin co‐
lonoscopy screening at age 40 (or 10 years before the youngest age of diagnosis), and they
should have an interval follow-up colonoscopy every 5 years. According to these recom‐
mendations, 2nd-degree relatives or relatives diagnosed >60 years of age are not considered
as a conferring a positive family history.
3.6. Polyposis syndromes
While the exact genetic predisposition for the majority of colon cancer remains unknown,
there are several well-known (and identifiable) cancer syndromes that a clinician must take
into account when making colon cancer screening advice. The most common of these is
Familial Adenomatous Polyposis. It affects roughly 1 in 5,000-7,000 individuals and confers
a 100% risk of eventual colorectal cancer, with the average age at diagnosis 40 (Bussey et al.,
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1978). These individuals should begin screening colonoscopy in adolescence (usually started
10-12 years old), and this should be repeated annually. Ultimately these patients should re‐
ceive prophylactic colectomy. Another such polyposis includes Attenuated Adenomatous
Polyposis. As opposed to FAP (which involves hundreds to thousands of polyps diffusely
spread throughout the colon), AAP is an oligopolyposis and typically involves <100 polyps.
These polyps are more often right-sided and with a flat morphology. Patient's typically be‐
gin to have polyps appear in the 4th-5th decade of life and an average age of diagnosis of
cancer at age 55 (Knudsen et al., 2003). Roughly 69% of patients with APP will eventually
develop colon cancer. These patients should begin screening colonoscopy at age 25 and this
should be repeated annually. Less common genetic polyposes a clinician may encounter in‐
volve: MUTYH-Associated Polyposis, Peutz-Jeghers Syndrome, and Juvenile Polyposis Syn‐
drome. MUTYH-Associated Polyposis is an autosomal recessive cancer syndrome
(heterozygotes with one affected allele are at increased risk, but homozygotes show the larg‐
est increase in risk). Variations in phenotype have been described, from hundreds to thou‐
sands of polyps distributed throughout the colon. Lifetime prevalence of colon cancer is
reported at 80% (Jenkins et al., 2006). These individuals should begin annual screening at
age 18-20. Clinicians may also encounter Peutz-Jeghers Syndrome, which is an autosomal
dominant disorder characterized by numerous hamartomatous polyps throughout the co‐
lon. These individuals carry a 39% lifetime risk of colon cancer and should have colonosco‐
py screening every 2-3 years beginning in their late teen years (McGarrity and Amos, 2006).
Finally, pediatric clinicians may encounter Juvenile Polyposis, which is an autosomal domi‐
nant condition characterized by numerous polyps throughout the gastrointestinal tract.
These individuals are often brought to the attention of a physician following an intestinal
obstruction or gastrointestinal bleed as a consequence of the numerous polyps. These pa‐
tients carry a 10-38% lifetime colon cancer risk and should be screened annually beginning
at age 15 (Howe et al., 1998; Jass et al., 1988).
3.7. Non-polyposis syndromes
The most common hereditary colon cancer syndrome is Lynch Syndrome, or Hereditary
Non-Polyposis Colorectal Cancer. This too is an autosomal dominant condition, which is
characterized by numerous, proximal adenomas. Affected individuals carry a 48-68% risk of
colon cancer by age 60, with the majority being diagnosed between age 40-50 (Mecklin et al.,
2007). Even more importantly, adenomas associated with HNPCC are typically more ag‐
gressive and advance to carcinoma quicker than would be otherwise expected. As such,
these individuals should begin screening at age 20, and this should be repeated every 1-3
years.
3.8. CRC risk associated with Inflammatory Bowel Disease
Nearly every clinician is sure to encounter a patient afflicted with Inflammatory Bowel Dis‐
ease (IBD). As such, it is important to recognize that these patients carry an increased risk
for colon cancer, and they cannot be treated as average-risk individuals. The entity is refer‐
red to as Colitis-Associated Cancer, or CAC, and the resultant risk of eventual colon cancer
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is related to the severity of disease (in both Ulcerative Colitis, and Crohn's Disease). The cu‐
mulative risk of colon cancer among patients with ulcerative colitis (U.C.) is thought to be
roughly 2% after 10-years of disease, and up to 18% after 30-years of disease (Eaden et al.,
2001). Although Crohn's Disease (C.D.) classically involves the small intestine, it can also in‐
volve the large bowel, which confers an increased risk of colon cancer as well. Crohn's pa‐
tients with large intestinal involvement carry an 8.3% risk of colon cancer after 30 years of
disease (Canavan et al., 2006). Currently, the recommendation is to begin screening both
U.C. and C.D. patients 8-10 years post-diagnosis, and institute 1-2 year screening intervals.
4. When to stop screening?
As touched on previously, equally important to the initiation of an effective screening pro‐
gram involves the optimal age to finish the screening process. The question could be posed:
“Why stop screening at all if it is an effective means to prevent morbidity and mortality
from colon cancer?” However several factors should be considered including the fact that
colonoscopy is not entirely without risk. The known complications associated with colono‐
scopy (e.g. bleeding, perforation, infection, diverticulitis), occur particularly in the elderly
population. Furthermore, and especially true with regard to colorectal cancer screening,
there exists a potentially long latency period from adenoma to carcinoma which may take
years and even decades in some individuals. Elderly patients with an adenoma seen on
screening may, and oftentimes do, perish as a result of other disease processes. Finally, lim‐
ited resources must also be taken into account. Each and every colonoscopy takes a concert‐
ed effort from a skilled colonoscopist and their support staff, and the required financial
means on the part of the patient and/or government. As such it is necessary to establish evi‐
dence-based guidelines on when patients can safely stop colon cancer screening. The follow‐
ing section will delve further into this topic and the current recommendations for age at
which to stop screening.
4.1. Complications from screening colonoscopy
In general, colonoscopy is a relatively safe, well-tolerated procedure by patients. The majori‐
ty of patients will never experience any complications, even if undergoing multiple colonos‐
copies throughout their lifetime. There are, however, significant and life-threatening
complications that can occur. Although rare, given the enormous number of colonoscopies
performed annually, it is important to be cognizant of the associated complications. In 2010,
an analysis was released tracking complications rates among 18 large studies and involving
over 685,000 colonoscopies (Ko and Dominitz, 2010). The most common complication seen
was lower gastrointestinal bleeding, at roughly 0.1-0.6%. Fortunately, the far majority of
these were not mortal bleeds. However, as most colonoscopies are undertaken in the outpa‐
tient setting, gastrointestinal hemorrhage can develop into a life-threatening event very
quickly in a non-monitored setting. Next most common, bowel perforation posed a risk of
less than 0.3% (Ko and Dominitz, 2010). These most often occur following barotrauma or
mechanical trauma to the bowel wall. Again, although exceedingly rare, a perforated bowel
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has the potential to be lethal. A perforation can be clinically evident immediately after the
incident occurs, however, small perforations in the bowel can lead to an insidious course
that can ultimately result in severe peritonitis and rapid clinical decompensation. Diverticu‐
litis is also a well-established complication of colonoscopy, with a rate estimated at
0.04-0.08% (Ko and Dominitz, 2010). There also exists the known entity of post-polypectomy
electrocoagulation syndrome (or post-polypectomy syndrome). Following electrocautery of
the bowel wall, there is risk for a partial or transmural burn of the bowel wall. In cases of a
transmural burn, patients experience symptoms of clinical peritonitis. This rarely proceeds
to actual peritonitis (radiography does not visualize actual perforated bowel with free air in
the peritoneum), and these patients can be managed via supportive care and antibiotics.
However, resultant hospitalization and treatment is not without its own associated risks and
costs, so this cannot be taken lightly either. The incidence of post-polypectomy electrocoagu‐
lation syndrome appears to be roughly 0.003%-0.01% (Ko and Dominitz, 2010). Infection as a
result of colonoscopy is exceedingly rare, and can most times be attributed to poor infection
control procedures involving equipment. Although the risk of transient bacteremia is postu‐
lated to be higher, the actual risk of an infection transmission purely as a result of colonosco‐
py is estimated at roughly 1 per 1.8 million procedures, with Pseudomonas and Salmonella
species being the most commonly identified (Spach et al., 1993). Other case-reportable com‐
plications have included splenic rupture, acute appendicitis, and subcutaneous emphysema
(Hirata et al., 1996; Humphreys et al., 1984; Kamath et al., 2009). Overall mortality from colo‐
noscopy remains controversial due to complicated comorbidities among those in studies
tracking colonoscopy-related mortality. Estimates range from 0%-0.09% (Ko and Dominitz,
2010). Less serious complications include nausea, vomiting, diarrhea and bloating. Fortu‐
nately, these are usually self-limited within several days following the colonoscopy. As evi‐
denced above, colonoscopy does have rare but serious complications. However, it is
important to note that complications are also related to the type of procedure performed
(screening colonoscopy or polypectomy) and the age of those undergoing the procedure.
In assessing the risk of complications from colonoscopies it is important to consider the type
of intervention to be employed during the procedure and the baseline characteristics of the
patient. Many studies have analyzed data pertaining to complications particularly associat‐
ed with different age groups. For example, a retrospective cohort study from 1994-2009 ex‐
amined these risks among over 43,000 patients ages 40-85 (Rutter et al., 2012). They pooled
hemorrhage, perforation, and diverticulitis as serious adverse events. They found an event
rate of 4.7/1000 screening colonoscopies and 6.8/1000 for follow-up colonoscopies. Interest‐
ingly, there were significant differences between age groups. Among ages 40-49 there was a
serious event rate of 4.2/1000, ages 50-64 3.7/1000, ages 65-74 7.9/1000, and for ages 75-84
13.3/1000. Thus the rate of complications clearly increases with age. They also noted an in‐
crease in events following polypectomy vs no intervention, however this proves less clini‐
cally relevant, as a clinician would certainly not forgo polypectomy based on this fact alone.
With the above data, and other studies like it (Gatto et al., 2003), it becomes evident that be‐
yond a certain age, colonoscopies may be causing more harm than good.
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4.2. Timing of progression from adenoma to carcinoma
As mentioned previously, the progression from adenoma to carcinoma may take years and
even decades. Some adenomas may never make the entire progression. The adenoma may
never acquire all the necessary genetic mutations, or simply, an individual may not live long
enough for the adenoma to significantly progress. As such, detecting an asymptomatic pol‐
yp in an elderly individual may have no significance whatsoever. In fact, while the risk of
colonoscopy complications poses a real threat, the adenoma may prove to have no bearing
on a patient's health. Currently, the most recent CDC data estimates that the average life ex‐
pectancy in the United States is 78.7 years (76.2 for males and 81.1 for females) (Centers for
disease control and prevention, 2012). This brings into question the utility of screening eld‐
erly age individuals. At what age will a screening colonoscopy likely provide no benefit to
the average-risk elderly patient?
The following discussion pertains to those at average-risk as identified previously in the
chapter. Individuals with predisposing factors (family history, genetic syndromes, inflam‐
matory disease) are not included in this grouping, and should continue with regularly
scheduled colonoscopies as defined previously. Many of the adenomas identified in these
high-risk groups have demonstrated a more rapid rate of progression to carcinoma, and
thus, they continue to need aggressive screening measures throughout their lifetime.
The incidence of colon cancer rises sharply with advancing age. Many studies have exam‐
ined this relationship over the past decades, and conclusive evidence supports this claim. In
fact, the rate of colon cancer among those over 65 years of age is 254.2/100,000 persons,
while the risk is substantially lower among those under 65, at 18.1/100,000 persons (NIH,
2009). Clearly, the elderly are at highest risk for developing colon cancer. Likewise, the eld‐
erly are also highest at risk for complications of colonoscopy. Extrapolating from the data
previously provided, the complication rate amongst individuals 75-84 is 1330/100,000 peo‐
ple. Therefore, there would be roughly 5 times as many serious complications from colono‐
scopy as there would be actual diagnoses of cancer in the age group 75-84. Further, studies
have been conducted looking at the chances of actually dying from colon cancer if diag‐
nosed late in life. Among those at age 75 (and in the middle quartile of expected life remain‐
ing), they have a 1.9% chance of actually dying from colon cancer (Walter and Covinsky,
2001). By age 85, this risk decreases to 1.6%. Among elderly patients with multiple co-mor‐
bidities, the chance of dying from colon cancer falls to 0.85%. For comparison, a 50-year old
male in the middle quartile of life expectancy has a 2.3% and female a 2.2% chance of even‐
tually dying from colon cancer. While the incidence of colon cancer increases with age, it ap‐
pears the mortality from the disease actually declines (if the cancer develops at the later
age). These elderly patients succumb to an illness other than colon cancer. Additionally,
studies have likewise examined the actual amount of life gained due to screening colonosco‐
py among different age groups. Here too there is a clear association with age. Among
asymptomatic individuals undergoing screening colonoscopy, younger age groups experi‐
ence a much larger benefit in terms of life gained. Among 50-54 year olds undergoing
asymptomatic screening, there is roughly 0.84 years of life years gained (Lin et al., 2006).
However, among individuals 80 years and above, only 0.13 additional years of life are
Issues in Screening and Surveillance Colonoscopy
http://dx.doi.org/10.5772/53111
45
gained. Thus, there is roughly a 6-fold difference in the actual effect of colon cancer screen‐
ing between the two groups. Although younger patients have a much lower chance of de‐
veloping colon cancer, they experience the lowest complication rate and benefit from the
largest amount of life years gained if diagnosed and treated.
4.3. The resource allocation factor
It is also equally important to consider allocation of valuable resources when debating
whether or not to forego colon cancer screening in the elderly. Colonoscopies, while cost-
effective, are expensive. Those uninsured may have to pay thousands of dollars for the pro‐
cedure, and those insured may have to pay copays, deductibles, etc. Moreover, the cost to
society is enormous. Considering there are currently 74,008,000 Americans age 55 and
above, there are millions of colonoscopies completed annually (Wagner et al., 1970). If there
are no established recommendations on when it is appropriate to stop colonoscopy screen‐
ing, millions of dollars will be spent for a procedure that may have minimal impact on the
health of those screened. Moreover, funding that could go toward more cost-effective treat‐
ments or screening programs would be needlessly diverted. Fortunately, the Affordable
Care Act (ACA) recently instated a policy in which Medicare and Medicaid “shall not im‐
pose any cost sharing requirements for evidence-based items or services that have in effect a
rating of ‘A’ or ‘B’ in the current recommendations of the United States Preventive Services
Task Force.” Therefore, the cost of a colonoscopy to the individual may be minimized, how‐
ever the cost to society will only grow. It is important to take into account the number of
providers who can safely and effectively offer colonoscopy screening as well. Studies have
demonstrated that colonoscopies performed by Gastroenterologists vs. non-Gastroenterolo‐
gists are both more cost-effective and more beneficial to the patient (i.e. trained endoscopists
are better at detection) (Hassan et al., 2012). In fact, the American Cancer Society estimates a
savings of roughly $200,000,000 per year if all colonoscopies were performed by Gastroen‐
terologists (currently both Gastroenterologists and non-Gastroenterologists are able to per‐
form colonoscopy). Unfortunately, the number of gastroenterologists available to provide
screening colonoscopies remains limited. Currently, there are roughly 10,400 practicing Gas‐
troenterologists in the United States. As screening compliance increases (and the absolute
number of individuals meeting the indication for screening increases as well), there will be a
severe shortage of practicing Gastroenterologists. As mentioned previously, as of now, there
is a 58.3% compliance rate to colon cancer screening. As this number increases, the limited
supply of Gastroenterologists will ultimately be overwhelmed. Even those who meet indica‐
tions for screening may be unable to obtain a colonoscopy in a timely manner. In effect, ev‐
ery colonoscopy performed on an elderly patient may mean one less colonoscopy for a
young, healthy individual. Simply put, there must be established guidelines followed by all
practitioners to ensure that screening colonoscopies are performed in the most cost-effective
and life-preserving manner. Therefore, it is of paramount importance to take resource allo‐
cation into account when advising patients on whether to proceed with colonoscopy or not.
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4.4. Evidence based approach to ending screening
The USPSTF currently recommends that colon cancer screening via colonoscopy be terminat‐
ed at age 75 (USPSTF, 2008). This recommendation is based upon a Decision Analysis publish‐
ed in 2008. Again, using two simulation models, the authors examined the average life-years
gained and the number of colonoscopies that would be required based upon the age at which
colonoscopy screening was stopped (and assuming a 10-year interval screening method in
average-risk individuals). The authors primarily tested ceasing colonoscopy at age 75 vs 85. In
essence, they found that by stopping screening at age 75, they decreased the number of life-
years gained by only 2-5/1000 people. However, the number of colonoscopies needed de‐
creased by 348-398/1000 people. The ranges given signify the results from both simulation
models. While some may argue that adding 2-5 life-years per 1000 people should take para‐
mount importance, this unfortunately cannot be the case given the limited resources as dis‐
cussed above. Until resources are infinite, it is necessary to funnel finances and medical staff
toward the population that will  most benefit  from screening. Distributing the additional
348-398 colonoscopies to a younger population will result in more life-years gained, lives
saved, and far fewer complications. Therefore, for the time being, it seems that ceasing colono‐
scopy screening at age 75 is both responsible and in the best interest of society.
4.5. Surveillance after late stage cancer diagnosis
Lastly, it is important to recognize that not all colonoscopies will be performed for strictly
screening purposes. Ultimately, the goal of colonoscopy is early diagnosis and curative
treatment by either polypectomy or bowel resection. However, as colon cancer is unfortu‐
nately still such a large cause of mortality in the United States and the screening rate is not
100%, many individuals will still be diagnosed with late-stage and unresectable colon can‐
cer. This then poses the question, what is the utility in surveillance colonoscopy in these in‐
dividuals?
To date, limited data exists concerning this topic. The primary treatment for patients with
diagnosed Stage IV inoperable colon cancer is palliative chemotherapy. Occasionally, che‐
motherapy may be able to shrink the tumor(s) to an operable state, but this is more often not
the case among late-stage diagnoses due to multiple metastases. Studies have analyzed
prognostic indicators among patients with inoperable disease and found that performance
status, ASA-class, CEA level, metastatic load, extent of primary tumor, and chemotherapy
were the only independent variables affecting prognosis in these patients (Stelzner et al.,
2005). While the initial diagnostic colonoscopy can provide valuable tissue data and infor‐
mation regarding depth of invasion, at this time surveillance colonoscopy does not appear
to play a role in the management beyond initial diagnosis. Given that there is no clear bene‐
fit to surveillance colonoscopy after diagnosis of inoperable colon cancer and there are a
multitude of risks associated with the procedure, surveillance colonoscopy is not indicated
in these patients.
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5. Factors that impact effective screening
Colonoscopy is an accurate and effective screening technique that is endorsed by many soci‐
eties including the American Cancer Society, U.S. Multi-society Task Force, American Col‐
lege of Radiology, and American College of Gastroenterology (ACG) (Levin et al., 2008; Rex
et al., 2009; USPSTF, 2008). While it may seem that screening for CRC is a well-established
and accepted standard of care, screening rates for CRC have only recently started to ap‐
proach that of other cancers. Increasing interest in the issue of best practice for CRC screen‐
ing is attributable to updates to screening guidelines as a result of recent studies indicating
significant mortality benefits. In addition to changes in the actual screening guidelines, the
goal of screening has shifted to focus on cancer prevention by removing polyps rather than
simply cancer detection (USPSTF, 2008). Important factors exist that impact the effectiveness
of available screening modalities for CRC, and these originate from physicians, patients, as
well as from society. While current recommendations support initiation of screening at age
50 for all average risk men and women, earlier initiation is advocated for those at higher risk
including African American men and women. Knowledge about these guidelines can im‐
pact screening practice. Consideration must also be given to the modality of CRC screening.
The ACG recommends colonoscopy as the preferred mode of screening, and the gold stand‐
ard given it diagnostic and therapeutic potential (Rex et al., 2009). Studies demonstrate that
most physicians overwhelmingly prefer colonoscopy as the test of choice (Guerra et al.,
2007). In fact, 70% of PCPs strongly believe colonoscopy is the best available colorectal can‐
cer-screening test. Furthermore, a large proportion of physicians are concerned over law‐
suits if they do not offer screening colonoscopies. The fear of facing a lawsuit over
colonoscopy complications can be outweighed by the fear of being sued if the procedure is
not offered at all (McGregor et al., 2010; Varela et al., 2010). While CRC screening saves
lives, the use of colonoscopy and other available options, remains suboptimal. Pinpointing
the reasons why people are not getting screened, either by choice or by circumstance, is es‐
sential in order to increase screening outcomes and compliance. There are unquestionably
many barriers to effective healthcare delivery in the US, let alone being able to appropriately
screen for CRC (Hoffman et al., 2011). Barriers can be sorted into a few main categories:
physician, patient, societal related factors. This section will touch on some of these obstacles.
5.1. The role of the physician in CRC screening
Physician recommendations play a crucial role in the decision to get screened for CRC (Zap‐
ka et al., 2011). A mere discussion of CRC screening at the time of an office visit may be suf‐
ficient and motivate patients to complete CRC screening. Given the prominence of the
physician factor it is important to consider elements that impact physician recommendation
of colonoscopy to their patients. Collegial norms, patient preferences, and published evi‐
dence including guidelines from the ACS and USPSF have been identified as important ele‐
ments. Physicians in the US favor endoscopy and often fail to adequately present
alternatives such as stool testing. One study found that 50% of the patients surveyed did not
receive the test they requested, and most underwent a colonoscopy instead (Hawley et al.,
2012). However, since all screening tests have some benefit, even if they are not on par with
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colonoscopy, physicians need to be sensitive and attuned to patient preferences. Techniques
other than colonoscopy may be more suitable for specific patients, given their individual cir‐
cumstances. For example, a recent study published in Cancer found that wealthy patients
frequently opt for colonoscopy while lower socioeconomic groups tended to choose at home
stool testing over endoscopy (Bandi et al., 2012). Patient preference varies by ethnicity as
well, with African Americans less likely to choose endoscopy than Caucasians (Dimou et al.,
2009). From their trial data, Inadomi and colleagues (Inadomi et al., 2012) predict that if co‐
lonoscopy were the only option offered, fewer patients would be screened. It is evident that
the choice of screening test should take into consideration not only the physician’s, but also
the patient’s perspective because some form of screening still remains superior to no screen‐
ing at all. Considering the evidence above, physicians should recommend one best option to
their patients using evidence-based medicine and taking into account patient specific fac‐
tors. CRC screening guidelines are complicated and offering multiple options still requires
shared decision making in practice (Zapka et al., 2011).
Although Medicare coverage has lessened these concerns, many physicians reported that
health  insurance  remains  very  influential  for  screening  recommendations  (White  et  al.,
2012).  Of note,  individuals  of  lower socioeconomic classes have expressed concerns that
they experience a lack of screening offers from doctors.  This is supported by physicians
who  admit  they  do  not  recommend  colonoscopy,  if  patients  do  not  have  insurance  or
ready access.  Another interesting difference in physician screening recommendation was
the age of the physician, with younger physicians recommending the test more. Although
this  is  merely  speculation,  younger  physicians  may  be  more  comfortable  ordering  this
newer test (Zapka et al., 2011).
In practice, physicians often fail to mention CRC screening because of limited time, compet‐
ing issues, and forgetfulness. At times the many pressing issues that need to be addressed,
preclude the lengthy discussion about available cancer screening tests. Additionally, many
patients only go to a clinic to address urgent issues. These clinics are often overbooked and
the main focus is to stabilize the acute problem. Some patients lack health insurance or are
unwilling to wait for appointments (Guerra et al., 2007). At best, some physicians may rec‐
ommend a follow up health maintenance visit. In addition, one national survey suggested
that the primary care physicians may not adequately discuss all test options available with
average risk patients because they are under the assumption that this will be addressed in
more depth by specialists. Screening rates suffer from lack of coordination between special‐
ists and PCPs (Doubeni et al., 2010). Physician forgetfulness and unfamiliarity with guide‐
lines is a preventable obstacle to screening (White et al., 2012). The screening and
surveillance recommendations differ significantly for a subset of CRC patients with heredi‐
tary syndromes. There is a marked lack of knowledge about screening guidelines for high-
risk populations based on family history and also ethnicity. Primary care physician
recommendations are often inconsistent with published guidelines. Among those most inti‐
mate with guidelines, the gastroenterologists, only a fraction recommended genetic counsel‐
ing, which is also a part of appropriate screening (White et al., 2012).
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Studies have suggested that physicians may not be fully aware of patient’s attitudes and val‐
ues towards screening. Physicians underestimated test discomfort and did not recognize the
importance of helping patients make informed decisions for screening. In addition, several
studies have shown that PCPs recommendations are affected by their demography includ‐
ing age, sex and ethnicity. For example, non-Caucasian physicians are less likely to recom‐
mend cancer screening compared to Caucasian doctors. Hispanic physicians in the US were
found to be less likely to recommend CRC screening. In a study in Australia, general practi‐
tioners of Middle Eastern ethnicity estimated CRC incidence to be lower in immigrants com‐
pared to patients born in Australia, which may have resulted in lower recommendations of
CRC screening for immigrants (Koo et al., 2012). Thus in general, primary care physicians
need greater awareness about CRC rates and screening.
While patients cite physician recommendation as the number one motivator for screening, oth‐
er factors might impact compliance. Research demonstrates that providing excessive choices
can be overwhelming subsequently leading to confusion and indecision. Selection of one pre‐
ferred alternative may help simplify the discussion about screening (Inadomi et al., 2012).
Studies that target physician recommendations have been shown to be more effective than
those that focus only on the patient (Guerra et al., 2007). In contrast, others argue that options
are needed because every CRC screening modality has its own strengths and limitations. Ad‐
ditionally, there does not seem to be a clear consensus among patients about preferred meth‐
ods. Thus, an important question arises: would patients be more willing to participate in
screening, if they are given the opportunity to choose? Engaging patients in the decision-mak‐
ing process can improve satisfaction by taking into account each patient’s unique needs. A pa‐
tient-centered approach improves screening compliance (Inadomi et al., 2012).
5.2. Patient-based factors in CRC screening
At the center of the discussion related to screening is the patient’s participation in complet‐
ing the process. While low participation rates in screening related to infrequent or lack of
follow-up is a difficult barrier to overcome, other factors are also important. It is notable that
most of the data about reasons for screening non-compliance comes from direct physician
report (Hoffman et al., 2011). Physicians reported offering screening to all of their high risk
and most of their average risk patients, and most were surprised at the low adherence rates.
Through their interactions with patients, physicians believed barriers to screening were fear
of the test, embarrassment, lack of insurance, and lack of knowledge about cancer and
screening. Interestingly, when patients were asked the same questions, they did not feel that
discomfort or embarrassment kept them from undergoing the procedure. Patients reported
lack of physician recommendation as one of the main factors for not getting tested, along
with lack of symptoms that might suggest a colon neoplasm (Jones et al., 2010). Of course
these studies are limited in terms of the particular patient population sampled and may not
be applicable to all patients; however, it is important to note that patients place great impor‐
tance on the conversation with primary care providers about CRC screening (Fenton et al.,
2011). Furthermore, this is directly linked to patient’s knowledge about CRC and screening.
Misconceptions continue to prevail as barriers to CRC screening, indicating a continued
Colonoscopy and Colorectal Cancer Screening - Future Directions50
need for brief, direct encouragement from providers to educate patients about screening,
particularly in the absence of symptoms or family history of CRC. Physicians can have great
impact on CRC screening, particularly with lifesaving colonoscopy, which is greatly un‐
derutilized in the US.
In a questionnaire investigating the patient barriers to CRC screening, hesitation about
screening was highest among never-screened respondents, intermediate among ever-
screened respondents who were overdue for testing, and lowest among the people adherent
with guidelines suggesting that different obstacles exist within each target group. The only
difference between those groups of patients is prior screening status. These results also dem‐
onstrate that people who have undergone screening are less fearful of the test itself, this
could be attributed to the fact that they have first hand experience instead of false informa‐
tion or misconceptions. Patients who are more educated are likely to be aware of the risks
and benefits of CRC screening (Winterich et al., 2011).
5.2.1. Patient attitudes, beliefs, and knowledge of CRC
Low compliance for CRC screening by patients can be attributed to several factors including
lack of insurance, cost, lack of knowledge of cancer and screening, not seeing a need for test‐
ing, embarrassment, lack of symptoms or health problems, fear of perceived pain, and anxi‐
ety of testing. This is in addition to failure by recommendation from a physician (Jones et al.,
2010). Studies have suggested that many patients dread getting ready for and having the
test and also worry about the test results. Additional research has found that the partici‐
pants did not understand the purpose of screening for cancer, were not able to distinguish
between screening tests from any other tests and did not realize that screening is performed
when a person feels well (Shokar et al., 2005).
Lack of knowledge is a major barrier to screening, particularly for immigrants, ethnic minor‐
ities, and underserved populations because of challenges in effective communication, as will
be discussed later. Studies looking into lack of knowledge about colon cancer screening
identified many other knowledge gaps including low health literacy. Some individuals did
not have a basic understanding of human anatomy and were not able to identify the location
of the colon nor its purpose. A subset of these individuals did not believe colon cancer exist‐
ed. Furthermore, a surprising amount of educated individuals could not accurately describe
the colon’s function, confusing it with the rectum and anus (Francois et al., 2009; Winterich
et al., 2011).
Those that had some fundamental knowledge of colon anatomy lacked an adequate under‐
standing about the causes and risk factors of colon cancer. Many individuals without symp‐
toms or family history do not feel concerned about this disease. Some are under the
impression that causes of colon cancer center around food and thought that bowel cleansing
was a good way to maintain or re-establish health. Others cited that they did not get
screened because they did not smoke, drink, eat unhealthy foods, or participate in anal sex,
all of which they perceived to be high-risk behaviors (Francois et al., 2009).
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In addition to poor understanding about colon cancer, many misperceptions about colono‐
scopy itself were identified. One study captured the reasons some people did not like colo‐
noscopy including that the preparation was “inconvenient”, “uncomfortable”, and involved
a “compromising position”. Men of all races and levels of educational attainment shared the
male specific gender barrier that they were turned off by the invasive nature of the colono‐
scopy. While males and females have similar screening rates, men expressed more initial
hesitation about screening because of the fear that it threatens their masculinity. Men who
associated their masculinity with these exams experienced them more negatively (Winterich
et al., 2011). Interestingly, Winterich et al. (Winterich et al., 2011) found that as education in‐
creased, men’s negative views of colonoscopy also seemed to increase. Most individuals of a
low-educational attainment generally described the colonoscopy as a “good” test because of
the culturally dominant view that medical care is important (Winterich et al., 2011).
5.2.2. Racial and ethnic disparities in CRC screening
As mentioned earlier, screening rates differ based on race and ethnic groups. The National
Health Interview Survey reported that racial disparities seen with CRC screening are related
to socioeconomic status, however, racial disparities persist despite coverage for CRC screen‐
ing in a Medicare population (Wilkins et al., 2012). Compared to whites, blacks and Hispan‐
ics are less likely to be screened. Overall rates of CRC screening are estimated to be 50% and
it is even lower for minorities. Screening rates vary even within a racial or ethnic group, e.g
among Asians, Koreans and Vietnamese have lower rates of screening; among whites, those
living in Appalachia have lower screening rates. Minority populations and low socioeco‐
nomic status are considered to be factors resulting in low CRC screening rates (Linsky et al.,
2011). Research studies also suggest that immigrants may experience unique barriers such as
language and cultural differences with their health care providers which can lead to poorer
communication about the importance of screening (Goel et al., 2003).
5.2.3. The language divide
Patients who do not speak English are less likely to be screened (Linsky et al., 2011). Accord‐
ing to the 2005-2007 American Community Survey, minorities comprise 26% of the popula‐
tion, and nearly 20% of Americans speak a language other than English at home. By 2050,
minorities could make up about half of the US population, with a similar increase in indi‐
viduals speaking a language other than English at home. Spanish speaking Hispanics are
43% less likely to receive CRC screening. Communication problems when discussing cancer
screening are also documented with Vietnamese Americans (Linsky et al., 2011). Additional‐
ly, for Creole speaking Haitian Americans the language barrier may also be a factor in com‐
municating with physicians (Francois et al., 2009). While patient-physician language
discordance presents a barrier, it is possible to address it through initiatives such as transla‐
tion services so that disparities in screening rates can be reduced.
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5.2.4. Cultural chasms
Cultural beliefs can result in lower screening rates, for example, Italian- Australians, Mace‐
donian-Australians and Greek- Australians were found to believe that nothing can be done
to treat ‘malignant’ cancers and that in fact, treatment of cancers may hasten death (Severino
et al., 2009). They also believe that consumption of ‘unnaturally’ grown foods, eating foods
sprayed with pesticides or experiencing strong emotions may cause cancer. Studies with Af‐
rican Americans have indicated that the lack of CRC knowledge, lack of physician recom‐
mendation, and a distrust of the health care system and providers impede screening; as well
as a fatalistic belief (beliefs that screening and treatments are ‘futile’ since it is in “God’s
hands”) which has also been reported as a barrier for CRC screening (James et al., 2002). A
subset of individuals connected colon cancer with “someone putting a curse on you” (Fran‐
cois et al., 2009). Studies in Latino population suggest that fatalistic attitudes and fear of can‐
cer are barriers to cancer screening and misconceptions about the causes of cancer as well as
perceived discomfort and embarrassment (Walsh et al., 2004).
Among other factors, family recommendations and cultural norms weighed heavily on per‐
ceptions about cancer and colonoscopy. For example, studies with Mexican and Hispanic
communities have cited the need for strategies to distribute the information without causing
any stigma or embarrassment. Privacy is highly valued in Mexican culture and thus individ‐
ualized educational sessions are a good approach. On the other hand, Hispanic communities
prefer group educational workshops. Emphasis on family and being healthy to provide for
the family was effective, as well as convincing women within families of the importance of
screening. Latinos also tend to see doctors only when sick and combine traditional and
home healing with physician prescribed medications. Religion and spirituality seem to im‐
pact the willingness to accept CRC screening, as does low income and less education (Ge‐
trich et al., 2012).
In a study of Haitian immigrants, preventive care was not emphasized by the community.
Haitians make one of the largest immigrant groups in US and have the lowest percentage of
insurance coverage. Instead of having a primary physician they seem to rely on emergency
rooms and do not see a doctor unless there is something wrong, there is not an operating
concept valuing ‘check ups’. Undocumented persons, seek help only in an emergency situa‐
tion and instead rely on home remedies. These individuals expressed that they simply did
not want to know if there was something wrong with them, because finding one problem
might lead to other ones (Francois et al., 2009).
5.2.5. Health literacy and educational outreach in CRC screening
Efforts to empower patients to become involved in their own care have proven to be effec‐
tive. Health literacy campaigns in New York City have improved CRC screening rates.
Community education is required to promote screening and public education campaigns are
shown to be effective. For example Mr. Polyp ads, a public service announcement from the
American Cancer Society, led many to ask their doctors about colonoscopies (Guerra et al.,
2007). Population based interventions aimed at increasing the demand for screening include,
reminders and incentives, mass and small media, group and one-on-one education. Bilin‐
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gual verbal communication and ‘word of mouth’ are also potentially very effective modali‐
ties. Blumenthal et al. (Blumenthal et al., 2010) tested three interventions intended to
increase the rate of CRC screening among African Americans. They concluded that group
education doubled screening rates and reduced out of pocket expenses. Furthermore, differ‐
ences in attitudes and perceived barriers among ethnic and minority population may need
culturally tailored interventions. Focus groups with Hispanics identified fear of finding can‐
cer and fear of embarrassment from the examination, as screening obstacles. With this infor‐
mation, Varela et al. (Varela et al., 2010) developed targeted educational materials to
promote colonoscopies among Hispanics. Similar educational materials could tap into faith-
based programs like the successful Witness Project for breast cancer.
5.2.6. Patient navigators and customized CRC screening
As previously mentioned, ethnic and cultural differences can pose a great barrier to effective
cancer screening. Patient advocates who help coordinate care provide an option for tackling
screening disparities. Termed patient navigators, these individuals are laypersons from the
community who help patients navigate the intricacies of the health care system (Lasser et al.,
2011). They can better address the unique needs of a patient and are responsible for almost
anything such as helping patients get insurance, finding transportation to doctors’ appoint‐
ments, healthcare education, and emotional support. For example, patients that require in‐
terpreters are found to be less compliant with screening recommendations. Providing
patients with a healthcare ambassador who speaks their preferred language has proven to
be a simple yet extremely powerful intervention. In a randomized controlled trial, recently
published in the Archives of Internal Medicine, researchers found quantifiable benefits from
assigning black and non-English speaking patients with a healthcare navigator. These pa‐
tients had a greater likelihood of being screened by FOBT than control subjects (33.6% vs
20.0%; P<.001) and were also more likely to undergo colonoscopy (26.4% vs 13.0%; P,.001).
Moreover, these patients had more adenomas detected (8.1% vs 3.9%; P<.06) and more cases
of CRC prevented (Lasser et al., 2011). This study highlights the importance of a multidisci‐
plinary approach to medicine. The impact of patient navigators, especially on urban and ra‐
cial minorities, is demonstrated by numerous studies (Chen et al., 2008; Lasser et al., 2011;
Lasser et al., 2009; Ma et al., 2009; Myers et al., 2008; Nash et al., 2006). A recent study found
patient navigators to be effective for Creole or Portuguese speaking patients. This model can
be observed in practice in Boston where Partners in Health routinely trains paramedical per‐
sonnel to assist in providing customized care for patients with HIV and TB in Haiti and
Rwanda.
The benefit of a team approach to healthcare is further evidenced by studies demonstrating
that the use of nurse practitioners and physicians assistants further streamlines healthcare
delivery and improves screening compliance. Moreover, telephone counseling and printed
materials can help improve follow up and overall quality of life in colorectal cancer survi‐
vors. Clouston et al. (Clouston et al., 2012) performed a study to evaluate use of a website
and telephones on CRC screening rates and concluded that both increased compliance sig‐
nificantly. However, a strong and trusting family physician-patient relationship must be
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maintained; otherwise, patients will experience a fundamental disconnect in the patient-
physician relationship that may discourage screening. The team-based approach does not
look to replace the physician, but can enhance patient-physician discourse.
Customized programs targeted to specific individuals may help improve patient participa‐
tion rates. Tailored screening guidelines have been advocated for certain groups based on
noted prevalence and anatomic location of colonic lesions in these populations. For example,
women are known to have an increased risk of right-sided polyps and cancer (Chu et al.,
2011), while African Americans tend to develop colorectal cancer at an earlier age (Agrawal
et al., 2005). The recommendation for tailored screening guidelines as suggested by the ACG
have the potential to help address existing disparities in CRC but must be balanced by ease
of implementation as well as healthcare financing concerns.
5.3. Public policies, outreach, and CRC screening
Although screening rates for CRC remain suboptimal, there has been an overall upward
trend. Endorsement from various recommending organizations helped promote awareness
of CRC screening in the medical community. Supported by population-based studies, gas‐
troenterology organizations have promoted screening with colonoscopy as the best screen‐
ing test. The healthcare policy to support CRC screening through Medicare reimbursement
was impactful in developing further acceptance. Medicare’s decision to support screening
colonoscopy had a significant impact on the popularity of this modality as other payers fol‐
lowed suit. With insurance companies willing to pay, doctors were more inclined to recom‐
mend screening and free to choose their preferred modality, colonoscopy. In fact,
gastroenterologists report they are now performing many more colonoscopies than before.
Some spend 50% to 80% of their time performing this one procedure, a dramatic increase
from before (Ransohoff, 2005).
Public perception and support has greatly impacted the implementation of screening, espe‐
cially colonoscopy. All of the aforementioned factors are geared at gaining strong popular
support, a necessary ingredient for any widespread screening practice. For example, pros‐
tate cancer screening became widely practiced on the basis of popular support, even without
evidence of mortality reduction. Arguably the most influential aspect of colon cancer and
screening awareness was the increasing presence of colonoscopy in the media. Famous peo‐
ple affected by colon cancer include Ronald Reagan, Audrey Hepburn, and Daryl Strawber‐
ry to name a few. Public interest in colonoscopy reached a turning point in March of 2000,
the first colon cancer awareness month. This initiative was spearheaded by news icon Katie
Couric, who advocated for CRC screening on the national stage by televising her own colo‐
noscopy after her husband’s death (Cram et al., 2003). Similar appearances of colonoscopy
in the media impacted CRC screening practices in the United States. Most recently, Dr. Oz
underwent a colonoscopy on his eponymous television show. An editorial featured in the
New York Times entitled “Going the distance-the case for true colorectal-cancer screening”
garnered further support for colonoscopies stating that sigmoidoscopy, that only screens
part of the colon, is comparable to mammography for only one breast. Numerous editorials
and front page articles have featured colonoscopies (Ransohoff, 2005). For example a news‐
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paper ad made the assertion, “your golden years deserve the gold standard of colon cancer
screening” (American College of Gastroenterology [ACG], 2012). Additional marketing on
the web has helped improve awareness among the public who increasingly use the web for
health information (Cohen and Adams, 2011).
5.3.1. Healthcare access
For patients to consider screening, it is important that to have insurance coverage, access to
healthcare or both. Only 24% of uninsured Americans, who do not have a usual source of
health care and are eligible, participate in CRC screening (Shapiro et al., 2012). Patients with
higher incomes are likely to have health insurance and tend to have a consistent source of
care. A recent systemic review reported that lower socioeconomic status was correlated with
a higher incidence and mortality rate (Wilkins et al., 2012). Subramanian et al. (Subramanian
et al., 2010) argue that when budgets are tight, options other than colonoscopies are better
for screening, basing this on the premise that some form of screening is better than no
screening at all. This study asserts that state and federal agencies have screening programs
for the uninsured and underinsured that may not be able to support colonoscopy in their
limited budget. However efficacy of the guaiac based fecal blood test depends on 100% com‐
pliance. This is often not practical and the study’s authors admit that colonoscopy is still a
better screening test if annual testing is not feasible.
In addition to financial access, geographic access can pose a problem for individuals in rural
areas. In New York City and other urban centers, most hospitals and many private practices
will offer colonoscopy; however, this is not the case in every part of the country. Several
studies have found lower screening rates in rural versus nonrural areas (Wilkins et al.,
2012). Geographic distance is a factor and individuals are less likely to be screened if the
nearest colonoscopy-offering center is over an hour away. The rural countries in the study
by Wilkins et al. (Wilkins et al., 2012) had higher poverty rates, lower educational level, lim‐
ited access to doctors, and less insurance coverage.
5.3.2. National programs
The benefits of a team approach to healthcare is further evidenced by national programs
that help promote patient awareness and education about CRC screening. Health policy ini‐
tiatives need to underscore the importance of screening programs to improve quality of can‐
cer screening. Cancer registries may be of use to identify and monitor the incidence, stage of
cancer and screening rate across regions. A CRC screening registry similar to Breast Cancer
Surveillance Consortium could be established to monitor rates of screening, overuse, quality
and complications. An ideal monitoring system should be able to estimate rates of screening
regardless of patient’s insurance status and demographic characteristics, assess use, appro‐
priateness and outcomes. Efforts should be made to support expansion, analysis and collab‐
oration of existing data sources and databases such as Clinical Outcome Research Initiative
(CORI) endoscopy data base, the Cancer Research Network (CRN) and the Computed To‐
mography Colonography Registry.
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5.3.3. Communication via current technologies
The use of systems strategies can improve physician delivery of healthcare. Systems strat‐
egies employ patient and physician screening reminders, performance reports of screening
rates, and electronic medical records (Yabroff et al., 2011). Given time constraints, remem‐
bering to perform all routine screenings for every patient is difficult. The increasing use of
electronic medical records (EMR) has helped physicians overcome this obstacle. Pop-up re‐
minders can help minimize forgetfulness, as well as the added pressure of remembering in‐
dividualized guidelines. These electronic prompts have the additional advantage of
flexibility, which allows for screening to account for the patient’s personal and family histo‐
ry. In one retrospective survey, the physicians that utilized this technology, which automati‐
cally provided appointments for CRC screening at a certain age, had the highest screening
rates (Fenton et al., 2011).
In addition to physician prompts, organized screening programs make use of patient re‐
minders to improve screening compliance. These programs reach out to all members of the
population due for CRC screening via mailed reminders (Levin et al., 2011). In addition to
outreach mailings, the Task Force on Community Preventive Services of the Centers for Dis‐
ease Control and Prevention recommend performance reports for doctors. Monetary incen‐
tive from insurance companies for completing age-appropriate screening is effective.
Additionally, better reimbursements are needed to encourage spending time on preventive
medicine (Guerra et al., 2007). Brouwers (Brouwers et al., 2011) conducted a systemic review
that included 66 randomized controlled studies and a cluster of randomized controlled tri‐
als. They concluded that client reminders, small media and provider audit and feedback ap‐
pear to increase screening rates significantly. Despite evidence that systems strategies are
effective, relatively few physicians report using a comprehensive plan to promote cancer
screening (Yabroff et al., 2011).
5.3.4. Health insurance coverage for colonoscopy
Ensuring health insurance coverage and usual source of care will most likely increase use
among those who have never been screened. Following Medicare’s example, private insur‐
ance coverage of CRC screening will be a step towards resolving the cost issue for physi‐
cians and patients. Asking patients to pay thousands of out of pocket expenses to undergo a
colonoscopy, will not help increase the rates of this life saving procedure. In a step to in‐
crease testing accessibility and affordability, the Affordable Care Act will ask insurers to
cover screening colonoscopies. This will include not only colonoscopy, but the use of anes‐
thesia (e.g. propofol) as opposed to conscious sedation (e.g., midazolam, fentanyl). Provid‐
ing increased options for sedation is likely to remove the patient barrier related to
discomfort and make it more likely that individuals will comply with colonoscopy as a life-
saving screening modality (Liu et al., 2012).
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6. Conclusion
This chapter has summarized the current body of knowledge related to colorectal cancer
screening and surveillance recommendations in the context of addressing risk stratification,
when to start and stop screening, as well as factors that impact screening rates. Overall,
screening, detection, and removal of precancerous lesions allow for the prevention of CRC.
It is notable that although strong evidence now exists for the mortality benefits of CRC
screening, significant disparities remain in the disease thus giving rise to opportunities to
address physician, patient, as well as societal factors that can improve screening rates.
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